http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 08 Aug 2024 11:37:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASLAN+Pharmaceuticals++++++++++++++++++Filed+by%3A+UBS+Group+AG/23572155.html si-local-file:///var/storage/secattach/20240808/23572155.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASLAN+Pharmaceuticals++++++++++++++++++Filed+by%3A+UBS+Group+AG/23572155.html Thu, 08 Aug 2024 11:37:00 -0400 ASLN O.11430892 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASLAN+Pharmaceuticals++++++++++++++++++Filed+by%3A+UBS+Group+AG/23572155.html si-local-file:///var/storage/secattach/20240808/23572155.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ASLAN+Pharmaceuticals++++++++++++++++++Filed+by%3A+UBS+Group+AG/23572155.html Thu, 08 Aug 2024 11:37:00 -0400 ASLN O.11430892 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/Press+Releases/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822 http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html <div class="xn-content"> <ul type="disc"><li><person>Stephen Doyle</person> has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>. He was most recently Chief Business Officer at <span value="NASDAQ-NMS:ASLN" idsrc="xmltag.org" >Aslan Pharmaceuticals</span>.</li><li><person>Mr Doyle</person> brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.</li></ul><p><span class="legendSpanClass"><location value="LU/au..brisbn" idsrc="xmltag.org" >BRISBANE, Australia</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2024</chron></span> /PRNewswire/ -- <span>QBiotics Group Limited</span> (<b>QBiotics</b>) is pleased to announce the appointment of <person>Stephen Doyle</person>, as Chief Executive Officer effective <chron>2 September 2024</chron>.</p> http://www.streetinsider.com/PRNewswire/QBIOTICS+WELCOMES+STEPHEN+DOYLE+AS+CHIEF+EXECUTIVE+OFFICER/23549172.html Mon, 05 Aug 2024 07:00:00 -0400 A.07497292 A.09222769 A.20422478 A.31197700 A.38659511 ASLN O.00385085 O.00450689 O.00831659 O.01159955 O.11430892 O.29774822